Current methods for attaching targeting ligands to liposomes and nanoparticles.
暂无分享,去创建一个
Robert Gurny | Eric Allémann | Franz Buchegger | R. Gurny | F. Buchegger | E. Allémann | Leila Nobs | Leila Nobs
[1] John W. Park,et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. , 1997, Biochemistry.
[2] A. Gabizon,et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[3] Jacques Barbet,et al. Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A , 1980, Nature.
[4] G. Storm,et al. Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. , 1993, Biochimica et biophysica acta.
[5] G. Weissmann,et al. Interaction of immunoglobulins with liposomes. , 1974, The Journal of clinical investigation.
[6] J. Kamps,et al. Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells. , 1999, Biochimica et biophysica acta.
[7] S. Zalipsky. Synthesis of an end-group functionalized polyethylene glycol-lipid conjugate for preparation of polymer-grafted liposomes. , 1993, Bioconjugate chemistry.
[8] F. Karush,et al. Attachment of immunoglobulin to liposomal membrane via protein carbohydrate. , 1984, Biochimica et biophysica acta.
[9] T M Allen,et al. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. , 1991, Biochimica et biophysica acta.
[10] G. Storm,et al. In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice. , 1992, Cancer research.
[11] E. Moase,et al. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. , 1995, Biochimica et biophysica acta.
[12] M. Bally,et al. A non-covalent method of attaching antibodies to liposomes. , 1987, Biochimica et biophysica acta.
[13] S. Kennel,et al. Binding of immunoglobulin G to phospholipid vesicles by sonication. , 1979, Biochemistry.
[14] F. Martin,et al. Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting. , 1982, The Journal of biological chemistry.
[15] S. Mao,et al. Biotinylation of antibodies. , 1994, Methods in molecular biology.
[16] V. Babaev,et al. Liposome uptake by cultured macrophages mediated by modified low-density lipoproteins. , 1985, Biochimica et biophysica acta.
[17] M. Akashi,et al. Synthesis of polystyrene nanospheres having lactose-conjugated hydrophilic polymers on their surfaces and carbohydrate recognition by proteins. , 1999, Journal of biomaterials science. Polymer edition.
[18] V. Torchilin,et al. Comparative studies on covalent and noncovalent immobilization of protein molecules on the surface of liposomes. , 1978, Biochemical and biophysical research communications.
[19] V. Torchilin,et al. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. , 2001, Biochimica et biophysica acta.
[20] P. Couvreur,et al. Surface-engineered nanoparticles for multiple ligand coupling. , 2003, Biomaterials.
[21] T. Nagai,et al. Preparation and evaluation of bovine serum albumin nanospheres coated with monoclonal antibodies. , 1988, Drug design and delivery.
[22] P. Couvreur,et al. Isobutyl cyanoacrylate nanoparticles as a solid phase for an efficient immunoradiometric assay. , 1986, Biomaterials.
[23] G. Adams,et al. Monoclonal antibody therapy for cancer. , 2003, Annual review of medicine.
[24] G. Scherphof,et al. An improved method for the covalent coupling of proteins to liposomes , 1985 .
[25] D. Pacchioni,et al. Antitumoral activity of liposomes and immunoliposomes containing 5-fluorouridine prodrugs. , 1997, Journal of pharmaceutical sciences.
[26] V. Torchilin,et al. Characterization of in vivo immunoliposome targeting to pulmonary endothelium. , 1990, Journal of pharmaceutical sciences.
[27] M. Ogris,et al. Nanoparticles bearing polyethyleneglycol-coupled transferrin as gene carriers: preparation and in vitro evaluation. , 2003, International journal of pharmaceutics.
[28] R. W. Baldwin,et al. Adsorption of monoclonal antibodies to polyhexylcyanoacrylate nanoparticles and subsequent immunospecific binding to tumour cells in vitro , 1983 .
[29] P. Jap,et al. Design of immunoliposomes directed against human ovarian carcinoma. , 1995, Biochimica et biophysica acta.
[30] J. Weinstein,et al. Receptor-mediated endocytosis of antibody-opsonized liposomes by tumor cells. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[31] H. Yanagie,et al. Liposomes Bearing Polyethyleneglycol-Coupled Transferrin with Intracellular Targeting Property to the Solid Tumors In Vivo , 2001, Pharmaceutical Research.
[32] T M Allen,et al. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. , 1998, Cancer research.
[33] V. Torchilin,et al. Incorporation of hydrophilic protein modified with hydrophobic agent into liposome membrane. , 1980, Biochimica et biophysica acta.
[34] Kazuo Maruyama,et al. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.
[35] V. Torchilin,et al. Biodegradable long-circulating polymeric nanospheres. , 1994, Science.
[36] Allan G. A. Coombes,et al. Surface Modification of Poly(lactide-co-glycolide) Nanospheres by Biodegradable Poly(lactide)-Poly(ethylene glycol) Copolymers , 1994, Pharmaceutical Research.
[37] P. Steerenberg,et al. Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo. , 1996, British Journal of Cancer.
[38] Ulrik B Nielsen,et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[39] Willis,et al. Ligand-targeted liposomes. , 1998, Advanced drug delivery reviews.
[40] S. P. Vyas,et al. Potential of polysaccharide anchored liposomes in drug delivery, targeting and immunization. , 2001, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[41] F. Martin,et al. Immunospecific targeting of liposomes to cells: a novel and efficient method for covalent attachment of Fab' fragments via disulfide bonds. , 1981, Biochemistry.
[42] J. Portnoy,et al. Monoclonal antibody-based assay for Alt a1, a major Alternaria allergen. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[43] Bally,et al. Clearance properties of liposomes involving conjugated proteins for targeting. , 1998, Advanced drug delivery reviews.
[44] V. Torchilin,et al. Phosphatidylinositol may serve as the hydrophobic anchor for immobilization of proteins on liposome surface , 1982 .
[45] L. Huang,et al. Monoclonal antibody targeting of liposomes to mouse lung in vivo. , 1989, Cancer research.
[46] V. Torchilin,et al. Preservation of antimyosin antibody activity after covalent coupling to liposomes. , 1979, Biochemical and biophysical research communications.
[47] J. Weinstein,et al. Binding of antigen-bearing fluorescent liposomes to the murine myeloma tumor MOPC 315. , 1979, Journal of immunology.
[48] M S Newman,et al. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. , 1997, Biochimica et biophysica acta.
[49] K. Maruyama,et al. Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice. , 1999, International journal of pharmaceutics.
[50] V. Torchilin,et al. Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: factors influencing targeted accumulation in the infarcted myocardium. , 1996, Biochimica et biophysica acta.
[51] Maruyama,et al. Possibility of active targeting to tumor tissues with liposomes. , 1999, Advanced drug delivery reviews.
[52] L. Huang,et al. Highly efficient immunoliposomes prepared with a method which is compatible with various lipid compositions. , 1989, Biochemical and biophysical research communications.
[53] R. Jain,et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[54] S. Gupta,et al. A three-step strategy for targeting drug carriers to human ovarian carcinoma cells in vitro. , 2002, Journal of biotechnology.
[55] V. Torchilin,et al. A new hydrophobic anchor for the attachment of proteins to liposomal membranes , 1986, FEBS letters.
[56] P. Walther,et al. Targeting of monoclonal antibody-coated liposomes to sheep red blood cells. , 1981, Biochemical and biophysical research communications.
[57] C. Benz,et al. Anti-HER2 immunoliposomes for targeted therapy of human tumors. , 1997, Cancer letters.
[58] V. Torchilin,et al. Intracytoplasmic gene delivery for in vitro transfection with cytoskeleton-specific immunoliposomes. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[59] L. Delattre,et al. Preparation of poly(D,L-lactide) nanoparticles assisted by amphiphilic poly(methyl methacrylate-co-methacrylic acid) copolymers , 2001, Journal of biomaterials science. Polymer edition.
[60] D. Papahadjopoulos,et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. , 1999, Pharmacological reviews.
[61] H von Briesen,et al. Preparation of avidin-labeled protein nanoparticles as carriers for biotinylated peptide nucleic acid. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[62] Alexander T. Florence,et al. Enhanced Oral Uptake of Tomato Lectin-Conjugated Nanoparticles in the Rat , 1997, Pharmaceutical Research.
[63] Robert Gurny,et al. Surface modification of poly(lactic acid) nanoparticles by covalent attachment of thiol groups by means of three methods. , 2003, International journal of pharmaceutics.
[64] Robert Gurny,et al. Drug-loaded nanoparticles : preparation methods and drug targeting issues , 1993 .
[65] R K Jain,et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.
[66] J. Irache,et al. Preparation and characterization of lectin-latex conjugates for specific bioadhesion. , 1994, Biomaterials.
[67] S. Ménard,et al. Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[68] V. Torchilin,et al. Targeted accumulation of polyethylene glycol‐coated immunoliposomes in infarcted rabbit myocardium , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[69] L. Huang,et al. Monoclonal antibody covalently coupled with fatty acid. A reagent for in vitro liposome targeting. , 1980, The Journal of biological chemistry.
[70] G. Scherphof,et al. UPTAKE AND PROCESSING OF IMMUNOGLOBULIN-COATED LIPOSOMES BY SUBPOPULATIONS OF RAT-LIVER MACROPHAGES , 1988 .
[71] John W. Park,et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[72] A. Maruyama,et al. Nanoparticle DNA carrier with poly(L-lysine) grafted polysaccharide copolymer and poly(D,L-lactic acid). , 1997, Bioconjugate chemistry.
[73] P. Volberding,et al. Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's Sarcoma , 1996, Journal of clinical pharmacology.
[74] J. Weinstein,et al. Antibody-mediated targeting of liposomes. Binding to lymphocytes does not ensure incorporation of vesicle contents into the cells. , 1978, Biochimica et biophysica acta.
[75] John W. Park,et al. Immunoliposomes for cancer treatment. , 1997, Advances in pharmacology.
[76] R. W. Baldwin,et al. Tissue distribution of poly(hexyl 2-cyanoacrylate) nanoparticles coated with monoclonal antibodies in mice bearing human tumor xenografts. , 1984, The Journal of pharmacology and experimental therapeutics.
[77] S M Moghimi,et al. Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.
[78] Y. Yarden,et al. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. , 1996, British Journal of Cancer.
[79] Douglas J. Goetz,et al. Ligand Coated Nanosphere Adhesion to E- and P-Selectin under Static and Flow Conditions , 2001, Annals of Biomedical Engineering.
[80] J. Petriz,et al. A novel strategy affords high-yield coupling of antibody to extremities of liposomal surface-grafted PEG chains. , 1999, Biochimica et biophysica acta.
[81] D. Barritault,et al. Biotinylated basic fibroblast growth factor is biologically active. , 1991, Analytical biochemistry.
[82] J. C. Domingo,et al. Preparation of long-circulating immunoliposomes using PEG-cholesterol conjugates: effect of the spacer arm between PEG and cholesterol on liposomal characteristics. , 2001, Chemistry and physics of lipids.
[83] G. Storm,et al. ACTIVE TARGETING WITH PARTICULATE CARRIER SYSTEMS IN THE BLOOD COMPARTMENT , 1995 .
[84] H. von Briesen,et al. Preparation of avidin-labelled gelatin nanoparticles as carriers for biotinylated peptide nucleic acid (PNA). , 2000, International journal of pharmaceutics.
[85] P. Meers,et al. Enzyme-activated targeting of liposomes. , 2001, Advanced drug delivery reviews.
[86] G. Fulci,et al. Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha. , 1997, Cancer research.
[87] J. J. Moore,et al. Specific interaction of myeloma tumor cells with hapten-bearing liposomes containing methotrexate and carboxyfluorescein. , 1980, Cancer research.
[88] F. Martin. CHAPTER 8.2 – Clinical pharmacology and antitumor efficacy of DOXIL (pegylated liposomal doxorubicin) , 1998 .
[89] P. Working,et al. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts , 1994, Cancer.
[90] F. Fazio,et al. Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[91] J M Irache,et al. Preparation of Ulex europaeus lectin-gliadin nanoparticle conjugates and their interaction with gastrointestinal mucus. , 1999, International journal of pharmaceutics.
[92] T. Allen,et al. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. , 1995, Biochimica et biophysica acta.
[93] L. Huang,et al. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. , 1995, Biochimica et biophysica acta.
[94] J H Senior,et al. Fate and behavior of liposomes in vivo: a review of controlling factors. , 1987, Critical reviews in therapeutic drug carrier systems.
[95] P. Couvreur,et al. Sorptive properties of antibodies onto cyanoacrylic nanoparticles , 1988 .
[96] L. Huang,et al. An improved method for covalent attachment of antibody to liposomes. , 1982, Biochimica et biophysica acta.
[97] D. Bloomgarden,et al. A general method for the introduction of enzymes, by means of immunoglobulin-coated liposomes, into lysosomes of deficient cells. , 1975, Proceedings of the National Academy of Sciences of the United States of America.